[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

The pathological hallmarks of Parkinson’s disease (PD) are marked loss of dopaminergic neurons in the substantia nigra pars compacta (SNc), which causes dopamine depletion in the striatum, and the presence of intracytoplasmic inclusions known as Lewy bodies in the remaining cells. It remains unclear why dopaminergic neuronal cell death and Lewy body formation occur in PD. The pathological changes in PD are seen not only in the SNc but also in the locus coeruleus, pedunculo pontine nucleus, raphe nucleus, dorsal motor nucleus of the vagal nerve, olfactory bulb, parasympathetic as well as sympathetic post-ganglionic neurons, Mynert nucleus, and the cerebral cortex (Braak et al. 2003). Widespread neuropathology in the brainstem and cortical regions are responsible for various motor and non-motor symptoms of PD. Although dopamine replacement therapy improves the functional prognosis of PD, there is currently no treatment that prevents the progression of this disease. Previous studies provided possible evidence that the pathogenesis of PD involves complex interactions between environmental and multiple genetic factors. Exposure to the environmental toxin MPTP was identified as one cause of parkinsonism in 1983 (Langston & Ballard 1983). In addition to MPTP, other environmental toxins, such as the herbicide paraquat and the pesticide rotenone have been shown to contribute to dopaminergic neuronal cell loss and parkinsonism. In contrast, cigarette smoking, caffeine use, and high normal plasma urate levels are associated with lower risk of PD (Hernan et al. 2002). Recently, Braak and coworkers proposed the “Dual Hit” theory, which postulated an unknown pathogen accesses the brain through two pathways, the nose and the gut (Hawkes et al. 2007). Subsequently, a prion-like mechanism might contribute to the propagation of αsynuclein from the peripheral nerve to the central nervous system (Angot et al. 2010). Approximately 5% of patients with clinical features of PD have clear familial etiology. Therefore, genetic factors clearly contribute to the pathogenesis of PD. Over the decade, more than 16 loci and 11 causative genes have been identified, and many studies have shed light on their implication in, not only monogenic, but also sporadic forms of PD. Recent studies revealed that PD-associated genes play important roles in cellular functions, such as mitochondrial functions, the ubiquitin-proteasomal system, autophagy-lysosomal pathway, and membrane trafficking (Hatano et al. 2009). In this chapter, we review the investigations of environmental and genetic factors of PD (Figure 1).

[1]  Y. Yamamura,et al.  Paralysis agitans of early onset with marked diurnal fluctuation of symptoms , 1973, Neurology.

[2]  P. Ballard,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983, The New England journal of medicine.

[3]  Langston Jw,et al.  Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1983 .

[4]  Y. Mizuno,et al.  Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. , 1987, Biochemical and biophysical research communications.

[5]  T. Nagatsu [Biochemistry of Parkinson's disease]. , 1988, Seikagaku. The Journal of Japanese Biochemical Society.

[6]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.

[7]  J. Langston,et al.  Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.

[8]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[9]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[10]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[11]  M. Goedert,et al.  Binding of α-Synuclein to Brain Vesicles Is Abolished by Familial Parkinson’s Disease Mutation* , 1998, The Journal of Biological Chemistry.

[12]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[13]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[14]  T. Kondo,et al.  Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q , 1998, Neurology.

[15]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[16]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[17]  M. Vila,et al.  α‐Synuclein Up‐Regulation in Substantia Nigra Dopaminergic Neurons Following Administration of the Parkinsonian Toxin MPTP , 2000, Journal of neurochemistry.

[18]  Todd B. Sherer,et al.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.

[19]  Heidi Phillips,et al.  Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System , 2000, Neuron.

[20]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[22]  D. Sulzer,et al.  Proteasomal inhibition leads to formation of ubiquitin/α‐synuclein‐immunoreactive inclusions in PC12 cells , 2001, Journal of neurochemistry.

[23]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[24]  Glenda M. Halliday,et al.  Clinical and pathological features of a parkinsonian syndrome in a family with an Ala53Thr α‐synuclein mutation , 2001 .

[25]  D. Hernandez,et al.  Lewy bodies and parkinsonism in families with parkin mutations , 2001, Annals of neurology.

[26]  G. Halliday,et al.  Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. , 2001, Annals of neurology.

[27]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[28]  M. Zigmond,et al.  A role for alpha-synuclein in the regulation of dopamine biosynthesis. , 2002, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[29]  Robert Burke,et al.  Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[31]  M. Zigmond,et al.  A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis , 2002, The Journal of Neuroscience.

[32]  J. C. Greene,et al.  Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Vila,et al.  The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model , 2003 .

[34]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[35]  M. Vila,et al.  The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. , 2003, Annals of the New York Academy of Sciences.

[36]  Leonidas Stefanis,et al.  Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. , 2004, Science.

[37]  S. Lipton,et al.  Molecular pathways to neurodegeneration , 2004, Nature Medicine.

[38]  N. Hattori,et al.  PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations , 2004, Neurology.

[39]  R. Edwards,et al.  Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  Peter T. Lansbury,et al.  Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy , 2004, Science.

[41]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[42]  A Dürr,et al.  Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. , 2004, Lancet.

[43]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[44]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[45]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[46]  D. Price,et al.  Axonal transport of human α‐synuclein slows with aging but is not affected by familial Parkinson's disease‐linked mutations , 2003, Journal of neurochemistry.

[47]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[48]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[49]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[50]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[51]  N. Hattori,et al.  A Combinatorial Code for the Interaction of α-Synuclein with Membranes* , 2005, Journal of Biological Chemistry.

[52]  R. Hilker,et al.  Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers , 2005, Annals of neurology.

[53]  N. Hattori,et al.  A combinatorial code for the interaction of alpha-synuclein with membranes. , 2005, The Journal of biological chemistry.

[54]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  P. Axelsen,et al.  The E46K mutation in alpha-synuclein increases amyloid fibril formation. , 2005, The Journal of biological chemistry.

[57]  Paul H. Axelsen,et al.  The E46K Mutation in α-Synuclein Increases Amyloid Fibril Formation* , 2005, Journal of Biological Chemistry.

[58]  Changan Jiang,et al.  Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.

[59]  I. Ferrer,et al.  Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. , 2006, Neurobiology of aging.

[60]  Sunhong Kim,et al.  Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.

[61]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[62]  A. Singleton,et al.  Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. , 2006, Annals of neurology.

[63]  A. Singleton,et al.  Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease , 2006 .

[64]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[65]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[66]  J. Trojanowski,et al.  Mechanisms of Parkinson's Disease Linked to Pathological α-Synuclein: New Targets for Drug Discovery , 2006, Neuron.

[67]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[68]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[69]  B. Oostra,et al.  A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan , 2006, Neurogenetics.

[70]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[71]  H. Qing,et al.  Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation , 2007, Acta Neuropathologica.

[72]  N. Hattori,et al.  Leucine-Rich Repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population , 2007, Neuroreport.

[73]  H. Braak,et al.  Parkinson's disease: a dual‐hit hypothesis , 2007, Neuropathology and applied neurobiology.

[74]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[75]  Salil K. Das,et al.  Cigarette smoke and dopaminergic system , 2007, Journal of biochemical and molecular toxicology.

[76]  H. Sershen,et al.  Increased Dopaminergic Neuron Sensitivity to 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in Transgenic Mice Expressing Mutant A53T α-Synuclein , 2008, Neurochemical Research.

[77]  N. Hattori,et al.  Sept4, a Component of Presynaptic Scaffold and Lewy Bodies, Is Required for the Suppression of α-Synuclein Neurotoxicity , 2007, Neuron.

[78]  N. Hattori,et al.  Leucine-rich repeat kinase 2 associates with lipid rafts. , 2007, Human molecular genetics.

[79]  Jun Guo,et al.  Inhibition of Vesicular Monoamine Transporter-2 Activity in α-Synuclein Stably Transfected SH-SY5Y Cells , 2007, Cellular and Molecular Neurobiology.

[80]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[81]  R. Hauser,et al.  Lewy body–like pathology in long-term embryonic nigral transplants in Parkinson's disease , 2008, Nature Medicine.

[82]  Hansong Deng,et al.  The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila , 2008, Proceedings of the National Academy of Sciences.

[83]  B. Jeon,et al.  α-Synuclein gene duplication is present in sporadic Parkinson disease , 2008, Neurology.

[84]  N. Zhang,et al.  alpha-Synuclein protofibrils inhibit 26 S proteasome-mediated protein degradation: understanding the cytotoxicity of protein protofibrils in neurodegenerative disease pathogenesis. , 2008, The Journal of biological chemistry.

[85]  S. Yazawa,et al.  Familial Parkinsonism with digenic parkin and PINK1 mutations , 2008, Movement disorders : official journal of the Movement Disorder Society.

[86]  Ted M. Dawson,et al.  PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.

[87]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[88]  N. Hattori,et al.  Pathogenesis of familial Parkinson’s disease: new insights based on monogenic forms of Parkinson’s disease , 2009, Journal of neurochemistry.

[89]  E. Waxman,et al.  Clinical and pathological characteristics of patients with Leucine‐rich repeat kinase‐2 mutations , 2009, Movement disorders : official journal of the Movement Disorder Society.

[90]  Beate Ritz,et al.  Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. , 2009, American journal of epidemiology.

[91]  Brian Spencer,et al.  Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein , 2009, Proceedings of the National Academy of Sciences.

[92]  Jie Shen,et al.  Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice , 2009, Journal of neurochemistry.

[93]  N. Hattori,et al.  Parkin stabilizes PINK1 through direct interaction. , 2009, Biochemical and biophysical research communications.

[94]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[95]  N. Sokol,et al.  Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression , 2010, Nature.

[96]  Christian Hansen,et al.  Are synucleinopathies prion-like disorders? , 2010, The Lancet Neurology.

[97]  N. Hattori,et al.  PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy , 2010, The Journal of cell biology.

[98]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[99]  Fabienne C. Fiesel,et al.  PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1 , 2010, Nature Cell Biology.

[100]  P. Nicotera,et al.  Paraquat and Parkinson's disease , 2010, Cell Death and Differentiation.

[101]  N. Hattori,et al.  PINK1 is recruited to mitochondria with parkin and associates with LC3 in mitophagy , 2010, FEBS letters.

[102]  D. Berwick,et al.  LRRK2 signaling pathways: the key to unlocking neurodegeneration? , 2011, Trends in cell biology.